<DOC>
	<DOCNO>NCT02501226</DOCNO>
	<brief_summary>Background . Major Depressive Disorder ( MDD ) highly prevalent associate great morbidity , mortality ( include suicide ) , healthcare cost . By 2030 , MDD become leading cause disability high-income country . Notably , among patient previous experience major depressive episode , indeed estimate 85 % patient suffer relapse . Two main factor associate significantly high risk relapse : poor medication adherence low self-efficacy disease management . Interestingly , issue could become target psychoeducational program chronic disease . Inded psychoeducational program depression recommend international guideline , yet propose France . Methods/Design : The investigator propose evaluate first French psychoeducational program depression name `` ENVIE '' multicenter randomize control trial . Its aim educate patient late knowledge depression effective treatment didactic interactive session . Patients experiment late innovate psychological skill ( acceptance commitment therapy ) cope depressive symptom maintain motivation behavioral activation . In total , 332 unipolar non-chronic ( &lt; 2 year ) outpatient moderate severe depression , without psychotic feature , randomly allocate add-on ENVIE program ( N=166 ) wait list ( N=166 ) . The follow-up last 15 month include 5 assessment visit ( enrollment , 3 , 6 , 9 , 12 , 15 month ) . Discussion . If propose trial show effectiveness intervention , also increase remission rate depress outpatient 15-months post-inclusion , addition improve treatment adherence patient , promote argument favor wide dissemination psychoeducational program depression .</brief_summary>
	<brief_title>Effectiveness First French Psychoeducational Program Unipolar Depression</brief_title>
	<detailed_description>The investigator propose study rate remission 15-month follow-up time achieve remission index episode multicentric randomize control trial use ENVIE program treatment usual versus treatment usual . The investigator include depressed subject suffer non first depressive episode well recurrent episode.The eligible patient randomize two group ( computer-generated randomisation 1 :1 ratio , block group 4 , stratify number episode : 1 , 2 , 3 ) . Only outpatient consult investigation centre recruit . Sociodemographic data , psychiatric diagnosis use Mini-International Neuropsychiatric Interview ( M.I.N.I . ) Screening Interview Axis II Disorder ( SCID-II ) borderline personality disorder , pharmacological treatment also recorded.Patients assessed clinician blind treatment allocation , inclusion ( intervention ) 3 month ( end intervention ) , 6 , 9 15 month inclusion .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<criteria>age 1865 year main diagnosis nonpsychotic nonchronic ( &lt; 2 year ) major depressive episode ( DSMIV criterion ) moderate severe intensity ( Montgomery Asberg Depression Scale score &gt; 24 ) take least one antidepressant able speak , read understand French ( able give write informed consent current diagnosis substance abuse dependence 6 month prior inclusion , exclude tobacco current psychotic feature duration current depressive episode &gt; 2 year current organic mental disorder mental retardation , severe comorbid medical condition lifetime history schizophrenia , schizoaffective bipolar disorder , manic , hypomanic , mixed episode accord DSMIV criterion sensory cognitive disability hospitalize fulltime time inclusion relationship employ sponsor investigator . We also exclude patient plan long stay outside region prevent compliance schedule visit , subject participate another trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Psychiatry</keyword>
	<keyword>Depression</keyword>
	<keyword>Psychoeducation</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>Treatment adherence</keyword>
	<keyword>Remission</keyword>
</DOC>